{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:51:20Z","timestamp":1787025080320,"version":"build-2736575974"},"reference-count":32,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Achieving and maintaining a glycated hemoglobin (HbA1c) level &amp;lt;7% in patients with type 2 diabetes (T2D) remains challenging, partly because of the daily insulin injection burden. Insulin efsitora alfa is a long-acting insulin Fc\u2013fusion protein designed for once-weekly administration, which may reduce injection burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The purpose of this analysis is to evaluate the efficacy and safety of once-weekly insulin efsitora alfa compared with once-daily basal insulin in adults with T2D, stratified by baseline insulin use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>PubMed, Web of Science, Scopus, and Cochrane CENTRAL were searched from inception through July 2025, along with ClinicalTrials.gov.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCTs) enrolling adults with T2D that compared once-weekly insulin efsitora alfa with once-daily basal insulin for \u226512 weeks were included. Six trials met eligibility criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION<\/jats:title>\n                    <jats:p>Two authors independently extracted data using a standardized form. The primary outcome was the mean change in HbA1c (%). Secondary outcomes included fasting plasma glucose, body weight, time in range, hypoglycemia, and adverse events. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>Six RCTs, including 4,116 participants, were analyzed. Efsitora demonstrated HbA1c reduction comparable to daily basal insulin in insulin-treated patients (mean difference [MD] \u20130.06% [95% CI \u20130.24, 0.11]; P = 0.48) and insulin-naive patients (MD \u20130.03% [95% CI \u20130.12, 0.06]; P = 0.51). Nocturnal hypoglycemia episodes were fewer with efsitora in both insulin-treated patients (risk ratio [RR] 0.82 [95% CI 0.68, 0.98]; P = 0.03) and insulin-naive patients (RR 0.71 [95% CI 0.52, 0.95]; P = 0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS<\/jats:title>\n                    <jats:p>All included trials were open-label, and follow-up duration was limited. Long-term outcomes, real-world adherence, and cost-effectiveness could not be fully assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Once-weekly insulin efsitora alfa demonstrates glycemic control and overall safety comparable to once-daily basal insulin in adults with T2D, with fewer nocturnal hypoglycemia episodes. Longer-term RCTs and real-world studies are needed to define its long-term clinical and economic impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/doc25-0066","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:20:36Z","timestamp":1773843636000},"page":"267-277","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness of Once-Weekly Insulin Efsitora Alfa in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.2337","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3088-517X","authenticated-orcid":false,"given":"Noha","family":"Hammad","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Port-Said University 1 , Port-Said, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelaziz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Health System, Albert Einstein College of Medicine 2 , Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Abouzkaly","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Sohag University 3 , Sohag, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdulrahman Saad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al Azhar University 4 , Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elazab","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, South Valley University 5 , Qena, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Atta","sequence":"additional","affiliation":[{"name":"Institute of Medicine, National Research Mordovia State University 6 , Saransk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-5783","authenticated-orcid":false,"given":"Raveendhara R.","family":"Bannuru","sequence":"additional","affiliation":[{"name":"American Diabetes Association 7 , Arlington, VA"},{"name":"Tufts University School of Medicine 8 , Boston, MA"},{"name":"Harvard Medical School 9 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-4916","authenticated-orcid":false,"given":"Nuha A.","family":"ElSayed","sequence":"additional","affiliation":[{"name":"American Diabetes Association 7 , Arlington, VA"},{"name":"Harvard Medical School 9 , Boston, MA"},{"name":"Brigham and Women\u2019s Hospital 10 , Boston, MA"},{"name":"Diabetes Education For All Foundation 11 , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026061813262973800_B1","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.2337\/dc26-S006","article-title":"6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes\u20142026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"key":"2026061813262973800_B2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.puhe.2023.10.015","article-title":"The prevalence of glycemic control in patients with type 2 diabetes treated with insulin: a systematic review and meta-analysis","volume":"225","author":"Pitak","year":"2023","journal-title":"Public Health"},{"key":"2026061813262973800_B3","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.2337\/dc26-S005","article-title":"5. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes\u20142026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"key":"2026061813262973800_B4","doi-asserted-by":"crossref","first-page":"e078015","DOI":"10.1136\/bmj-2023-078015","article-title":"Insulin for people with type 2 diabetes mellitus","volume":"386","author":"Vanderpant","year":"2024","journal-title":"BMJ"},{"key":"2026061813262973800_B5","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"key":"2026061813262973800_B6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/ds18-0005","article-title":"Insulin initiation and titration in patients with type 2 diabetes","volume":"32","author":"Chun","year":"2019","journal-title":"Diabetes Spectr"},{"key":"2026061813262973800_B7","doi-asserted-by":"crossref","first-page":"e000203","DOI":"10.1136\/bmjdrc-2016-000203","article-title":"Psychological barriers to optimal insulin therapy: more concerns in adolescent females than males","volume":"4","author":"Wisting","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026061813262973800_B8","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/S0140-6736(25)01069-4","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Blevins","year":"2025","journal-title":"Lancet"},{"key":"2026061813262973800_B9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.31128\/AJGP-04-20-5322","article-title":"Strategies to simplify complex medication regimens","volume":"50","author":"Bell","year":"2021","journal-title":"Aust J Gen Pract"},{"key":"2026061813262973800_B10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eprac.2024.12.013","article-title":"Optimal use of once-weekly basal insulin efsitora alfa in type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"31","author":"Dutta","year":"2025","journal-title":"Endocr Pract"},{"key":"2026061813262973800_B11","doi-asserted-by":"crossref","first-page":"109115","DOI":"10.1016\/j.jdiacomp.2025.109115","article-title":"Degludec insulin versus efsitora insulin in diabetes mellitus management: a systematic review and meta-analysis","volume":"39","author":"de Oliveira","year":"2025","journal-title":"J Diabetes Complications"},{"key":"2026061813262973800_B12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026061813262973800_B13","unstructured":"The Cochrane Collaboration\n          . Cochrane handbook for systematic reviews of interventions. Accessed 26 November 2024. Available from https:\/\/training.cochrane.org\/handbook"},{"key":"2026061813262973800_B14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2013a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026061813262973800_B15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026061813262973800_B16","unstructured":"The Cochrane Collaboration\n          . Chapter 6: choosing effect measures and computing estimates of effect. Accessed 12 September 2025. Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-06"},{"key":"2026061813262973800_B17","unstructured":"StataCorp LLC\n          . Stata 19 is here. Accessed 12 September 2025. Available from https:\/\/www.stata.com\/stata-news\/news40-2\/"},{"key":"2026061813262973800_B18","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","article-title":"Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment","volume":"391","author":"Wysham","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061813262973800_B19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2502796","article-title":"Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061813262973800_B20","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0140-6736(25)01044-X","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Philis-Tsimikas","year":"2025","journal-title":"Lancet"},{"key":"2026061813262973800_B21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-8587(22)00388-6","article-title":"Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study","volume":"11","author":"Frias","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061813262973800_B22","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2337\/dc22-2396","article-title":"Once-weekly basal insulin Fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial","volume":"46","author":"Bue-Valleskey","year":"2023","journal-title":"Diabetes Care"},{"key":"2026061813262973800_B23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1089\/dia.2021.0164","article-title":"Missed and mistimed insulin doses in people with diabetes: a systematic literature review","volume":"23","author":"Robinson","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"2026061813262973800_B24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40261-024-01405-8","article-title":"Pharmacokinetic properties of a once-weekly fixed-ratio combination of insulin icodec and semaglutide compared with separate administration of each component in individuals with type 2 diabetes mellitus","volume":"44","author":"Westergaard","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2026061813262973800_B25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.122.001105","article-title":"Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein","volume":"382","author":"Moyers","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"2026061813262973800_B26","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/dom.14956","article-title":"Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes","volume":"25","author":"Heise","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026061813262973800_B27","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026061813262973800_B28","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(23)00520-2","article-title":"Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial","volume":"401","author":"Mathieu","year":"2023","journal-title":"Lancet"},{"key":"2026061813262973800_B29","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s13300-024-01652-0","article-title":"Perspectives and preferences of people with type 2 diabetes for the attributes of weekly insulin","volume":"15","author":"Gelsey","year":"2024","journal-title":"Diabetes Ther"},{"key":"2026061813262973800_B30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.eprac.2025.01.009","article-title":"Perioperative and periprocedural management of once-weekly insulin treated patients","volume":"31","author":"Houlden","year":"2025","journal-title":"Endocr Pract"},{"key":"2026061813262973800_B31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2147\/CEOR.S539841","article-title":"Cost-effectiveness of once-weekly insulin icodec versus daily basal insulins in Chinese adults with T2DM: a treatment-background stratified analysis","volume":"17","author":"Xie","year":"2025","journal-title":"Clinicoecon Outcomes Res"},{"key":"2026061813262973800_B32","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s11606-023-08222-3","article-title":"Rates and correlates of uptake of continuous glucose monitors among adults with type 2 diabetes in primary care and endocrinology settings","volume":"38","author":"Mayberry","year":"2023","journal-title":"J Gen Intern Med"}],"container-title":["Diabetes Obesity and Cardiometabolic CARE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/2\/267\/859541\/docm250066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article-pdf\/1\/2\/267\/859541\/docm250066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:26:38Z","timestamp":1781803598000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/docm-care\/article\/1\/2\/267\/164612\/Comparative-Effectiveness-of-Once-Weekly-Insulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/doc25-0066","relation":{},"ISSN":["3067-3518","3067-3534"],"issn-type":[{"value":"3067-3518","type":"print"},{"value":"3067-3534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}